Categories: Health

Regen BioPharma Discusses Potential Impact of HemaXellerate on Chemotherapy Treament Market

SAN DIEGO, Aug. 15, 2025 (GLOBE NEWSWIRE) — Regen BioPharma, Inc. (OTC ID: RGBP and RGBPP) today provided further insight into its planned Phase 1 clinical trial of HemaXellerate, the company’s innovative stem cell-derived therapy, which has already received U.S. FDA clearance. While the initial focus is on treating aplastic anemia, a rare orphan indication, Regen BioPharma is evaluating expanded applications for this groundbreaking therapy in markets poised for significant growth.

Regen sees substantial potential in treating chemotherapy-induced bone marrow suppression, a market projected to be valued at well in excess of $1 billion annually. HemaXellerate is designed to stimulate bone marrow regeneration following injury caused by autoimmune conditions, chemotherapy, or radiation.

  • HemaXellerate is comprised of cells extracted from the patient’s own fat tissue and processed using a proprietary method to induce a biological response in the patient that heals damaged bone marrow and restores the body’s ability to generate healthy blood cells.

“Aplastic anemia patients without access to bone marrow transplantation face limited options,” said Dr. David Koos, Chairman and CEO of Regen BioPharma. “With FDA clearance to begin clinical trials, HemaXellerate has the potential to redefine the treatment landscape—not just for aplastic anemia but for a wide range of hematological disorders. This is a pivotal moment for our company as we work to deliver life-changing therapies to patients worldwide.”

To ensure the trial’s success, Regen BioPharma has partnered with a clinical research organization (CRO) known for its expertise in conducting complex trials. Once initiated, the study is expected to reach completion within 12 to 14 months.

  • Opportunity: Aplastic anemia is a rare disease with high unmet medical need, offering the potential for accelerated regulatory pathways and market exclusivity.
  • Massive Market Potential: Expansion into chemotherapy-induced bone marrow suppression could unlock a multi-billion-dollar market.
  • Strategic Execution: Collaboration with a leading CRO ensures focused execution and timeline adherence.

About Regen BioPharma, Inc.

Regen BioPharma, Inc. is a publicly traded biotechnology company (OTC ID: RGBP) and (OTC ID: RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on mRNA and small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com.

Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject to include, but are not limited to, the effect of government regulation, competition and other material risks.

CONTACT INFORMATION:

Regen BioPharma Inc.
David R. Koos, Ph.D.
Chairman & Chief Executive Officer
+1-619-722-5505 Phone
Email: david.koos@regenbiopharmainc.com or
david.koos@regenbiopharma.com
X (formerly twitter): https://x.com/TheRegenBio 

GlobeNews Wire

Recent Posts

Manulife and UpLink Announce Winners of the ‘Innovating for Asia’s Demographic Future Challenge’

Challenge is second of three in a multiyear partnership to help shape the future of…

29 minutes ago

Manulife Champions Longevity in Asia with Inaugural Symposium and Enhanced ManulifeMOVE

Over 1,000 attendees convened for the landmark event, graced by the presence of Minister of…

29 minutes ago

Casio India brings its First-Ever Automatic watch to India with the Launch of EDIFICE EFK-100 series

~The legacy of Casio now transcends to the world of automatic timepieces, blending motorsport-inspired design…

3 hours ago

A New Era in Smart Living: ECOVACS Unveils DEEBOT X11 with PowerBoost Technology and Expands Service Robot Portfolio at IFA 2025

ECOVACS is introducing its groundbreaking robotic vacuum cleaner DEEBOT X11 at IFA 2025, taking innovation…

3 hours ago

ACKO Launches Support Initiative to Help Vehicle Owners Book HSRP Plates Before Maharashtra’s Extended Deadline

BENGALURU, India, Sept. 6, 2025 /PRNewswire/ -- The Maharashtra government has extended the deadline for installing…

3 hours ago

Yutong Bus Link+ Empowers Fleets with Intelligent Management and Higher Operational Efficiency

ZHENGZHOU, China, Sept. 5, 2025 /PRNewswire/ -- Yutong Bus ("Yutong", SHA: 600066), a leading global electric…

3 hours ago